It provides higher specificity for detecting clinically significant prostate cancer, the ability to reduce unnecessary biopsies by up to 30.1% at 90% sensitivity, an Area Under the Curve (AUC) of 0.708 for overall prostate cancer detection, and outperforming individual PSA components [44]. The gene discussed is KLK3; the disease is prostate carcinoma.